

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | The mammalian ste20-like kinases 1/2 (MST1/2) which is a core component in the Hippo pathway in mammals, is related in cell growth, controlling organ size and maintaining organ homeostasis[1]. XMU-MP-1 is a potent and selective inhibitor of MST1/2 with IC50 value of 71.1 nM and 38.1 nM against MST1 and MST2, respectively[2]. XUM-MP-1 was added to a variety of cell lines including RAW264.7, USOS, SW480, SNU-423, RPE1 and HepG2, and the inhibition of hydrogen peroxide (H2O2)–stimulated MOB1 phosphorylation and MST1/2 autophosphorylation started at concentration of 1 and 3 μM for all cell lines measured by immunoblotting assay after incubating with XMU-MP-1 for 3 hours. In Sprague-Dawley rats, after intraperitoneal administration of 1 mg/kg XMU-MP-1, the maximal phosphorylation inhibition of MOB1 and YAP was achieved between 1.5 and 6 hours in the liver tissue. The wild-type mice were treated with XMU-MP-1 once a day before a two-thirds partial hepatectomy followed by daily treatment for 7 days. The treatment of XMU-MP-1 could enhance liver regeneration and increase the amounts of Ki67-positive cells and YAP-positive cells in the liver, as well as liver/body weight ratio compared with the control group. |
| 作用机制 | XMUMP-1 target the ATP-binding site of the kinases MST1/2. |
| Concentration | Treated Time | Description | References | |
| LX-2 cells | 5 µM | 24 h | Block the Hippo signaling pathway and attenuate the inhibitory effect of ADMSCs on HSCs | Stem Cell Res Ther. 2024 Oct 24;15(1):378. |
| C2C12 cells | 1 μM | 6 h | Restores YAP/TAZ nuclear localization in BAG3-depleted cells | Biomaterials. 2021 Oct;277:121097. |
| NSCLC cell lines H1299 | 1 mM | 24 h | XMU-MP-1 treatment partially reversed ACADL-induced YAP phosphorylation and promoted nuclear accumulation of YAP. | Cancer Cell Int. 2024 Feb 24;24(1):86. |
| NSCLC cell lines A549 | 1 mM | 24 h | XMU-MP-1 treatment partially reversed ACADL-induced YAP phosphorylation and promoted nuclear accumulation of YAP. | Cancer Cell Int. 2024 Feb 24;24(1):86. |
| BMDMs | 3μM | 6 h | After inhibiting MST1/2 activity, RNA-Seq and qRT-PCR results showed increased expression of inflammatory cytokines under LPS stimulation and decreased expression of M2 markers under IL-4+IL-13 stimulation. | Int J Biol Sci. 2024 Jan 12;20(3):1004-1023. |
| RAW 264.7 | 5μM | 4-6 h | After pretreatment with XMU-MP-1, RAW 264.7 cells showed inhibited MST1/2 activity and changes in Hippo pathway-related protein expression under LPS or IL-4+IL-13 stimulation. | Int J Biol Sci. 2024 Jan 12;20(3):1004-1023. |
| Huh7 cells | 10 μM | 12 h | XMU-MP-1 significantly reduced HAMP expression in Huh7 cells, even in the presence of BMP6. | Research (Wash D C). 2023 Nov 30;6:0281. |
| Primary hepatocytes | 10 μM | XMU-MP-1 significantly reduced Hamp expression in primary hepatocytes from both Tmprss6-LKO mice and control littermates. | Research (Wash D C). 2023 Nov 30;6:0281. | |
| C3H10T1/2 cells | 10 μM | 24 h | XMU-MP-1 increased the expression of Col2α1 and Col9α2. | Nat Commun. 2020 Jan 15;11(1):282. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Achilles tendon punch injury model | Intraperitoneal | 2 mg/kg | Three times a week for 3 weeks | XMU-MP-1 suppressed ectopic bone formation | Nat Commun. 2025 Jan 16;16(1):749 |
| Mice | DBA/1 mouse model | Intraperitoneal injection | 2 mg/kg | Three times a week for 16 weeks | To investigate the effect of XMU-MP-1 on new bone formation in DBA/1 mouse model, results showed that XMU-MP-1 significantly reduced new bone formation. | Ann Rheum Dis. 2021 Jul;80(7):891-902 |
| Nude mice | NSCLC xenograft model | Intraperitoneal injection | 1 mg/kg | Twice a week for three weeks | XMU-MP-1 partially counteracted the inhibitory effect of ACADL on NSCLC cell growth. | Cancer Cell Int. 2024 Feb 24;24(1):86. |
| Mice | LPS-induced lung injury model | Intraperitoneal injection | 2 mg/kg | Single injection, lungs collected at 12 and 24 hours post-infection | Mice treated with XMU-MP-1 in the LPS-induced lung injury model exhibited more severe inflammatory response and tissue damage, increased proportion of CD86-positive cells in lung tissue, and elevated mRNA expression of IL-1β, IL-6, and TNF-α. | Int J Biol Sci. 2024 Jan 12;20(3):1004-1023. |
| Dose | Mice: 1 mg/kg - 3 mg/kg[2] |
| Administration | i.p. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.40mL 0.48mL 0.24mL |
12.01mL 2.40mL 1.20mL |
24.01mL 4.80mL 2.40mL |
|
| CAS号 | 2061980-01-4 |
| 分子式 | C17H16N6O3S2 |
| 分子量 | 416.48 |
| SMILES Code | O=S(C1=CC=C(NC2=NC=C(C(N(C)C3=C4SC=C3)=N2)N(C)C4=O)C=C1)(N)=O |
| MDL No. | MFCD30377214 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | YRDHKIFCGOZTGD-UHFFFAOYSA-N |
| Pubchem ID | 121499143 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 6 mg/mL(14.41 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1